日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/02/24 | 1,742 | 1,744 | 1,738 | 1,740 | -2 | -0.1% | 1,500 |
| 2023/02/22 | 1,739 | 1,748 | 1,738 | 1,742 | -2 | -0.1% | 1,900 |
| 2023/02/21 | 1,755 | 1,755 | 1,743 | 1,744 | +1 | +0.1% | 2,400 |
| 2023/02/20 | 1,733 | 1,756 | 1,733 | 1,743 | +20 | +1.2% | 2,500 |
| 2023/02/17 | 1,732 | 1,735 | 1,723 | 1,723 | -4 | -0.2% | 800 |
| 2023/02/16 | 1,732 | 1,737 | 1,719 | 1,727 | -10 | -0.6% | 6,200 |
| 2023/02/15 | 1,737 | 1,742 | 1,727 | 1,737 | -17 | -1% | 4,400 |
| 2023/02/14 | 1,729 | 1,762 | 1,727 | 1,754 | +8 | +0.5% | 5,600 |
| 2023/02/13 | 1,750 | 1,753 | 1,735 | 1,746 | ±0 | ±0% | 6,100 |
| 2023/02/10 | 1,731 | 1,763 | 1,730 | 1,746 | +15 | +0.9% | 7,000 |
| 2023/02/09 | 1,737 | 1,741 | 1,731 | 1,731 | -6 | -0.3% | 5,800 |
| 2023/02/08 | 1,706 | 1,737 | 1,706 | 1,737 | +26 | +1.5% | 1,400 |
| 2023/02/07 | 1,712 | 1,725 | 1,711 | 1,711 | ±0 | ±0% | 4,100 |
| 2023/02/06 | 1,708 | 1,711 | 1,700 | 1,711 | +3 | +0.2% | 1,200 |
| 2023/02/03 | 1,703 | 1,714 | 1,700 | 1,708 | +2 | +0.1% | 2,700 |
| 2023/02/02 | 1,720 | 1,720 | 1,690 | 1,706 | -2 | -0.1% | 6,600 |
| 2023/02/01 | 1,734 | 1,734 | 1,693 | 1,708 | -80 | -4.5% | 12,000 |
| 2023/01/31 | 1,760 | 1,789 | 1,760 | 1,788 | +33 | +1.9% | 5,100 |
| 2023/01/30 | 1,758 | 1,787 | 1,755 | 1,755 | +9 | +0.5% | 20,900 |
| 2023/01/27 | 1,749 | 1,755 | 1,742 | 1,746 | ±0 | ±0% | 3,000 |
| 2023/01/26 | 1,740 | 1,758 | 1,733 | 1,746 | +9 | +0.5% | 6,600 |
| 2023/01/25 | 1,723 | 1,738 | 1,709 | 1,737 | +13 | +0.8% | 8,900 |
| 2023/01/24 | 1,714 | 1,725 | 1,702 | 1,724 | +10 | +0.6% | 5,700 |
| 2023/01/23 | 1,718 | 1,729 | 1,703 | 1,714 | -1 | -0.1% | 4,000 |
| 2023/01/20 | 1,714 | 1,716 | 1,704 | 1,715 | -3 | -0.2% | 2,500 |
| 2023/01/19 | 1,700 | 1,718 | 1,695 | 1,718 | +25 | +1.5% | 5,000 |
| 2023/01/18 | 1,675 | 1,704 | 1,675 | 1,693 | +18 | +1.1% | 4,900 |
| 2023/01/17 | 1,677 | 1,679 | 1,651 | 1,675 | -2 | -0.1% | 5,000 |
| 2023/01/16 | 1,671 | 1,680 | 1,670 | 1,677 | +6 | +0.4% | 3,200 |
| 2023/01/13 | 1,662 | 1,678 | 1,662 | 1,671 | +13 | +0.8% | 3,900 |
| 2023/01/12 | 1,673 | 1,674 | 1,657 | 1,658 | -23 | -1.4% | 2,900 |
| 2023/01/11 | 1,677 | 1,691 | 1,668 | 1,681 | -6 | -0.4% | 5,000 |
| 2023/01/10 | 1,663 | 1,687 | 1,660 | 1,687 | +25 | +1.5% | 4,200 |
| 2023/01/06 | 1,645 | 1,663 | 1,645 | 1,662 | +21 | +1.3% | 2,100 |
| 2023/01/05 | 1,647 | 1,649 | 1,640 | 1,641 | ±0 | ±0% | 1,700 |
| 2023/01/04 | 1,648 | 1,650 | 1,641 | 1,641 | -16 | -1% | 3,000 |
| 2022/12/30 | 1,644 | 1,660 | 1,642 | 1,657 | +13 | +0.8% | 3,700 |
| 2022/12/29 | 1,634 | 1,644 | 1,634 | 1,644 | +10 | +0.6% | 1,900 |
| 2022/12/28 | 1,642 | 1,642 | 1,634 | 1,634 | -17 | -1% | 8,100 |
| 2022/12/27 | 1,645 | 1,655 | 1,644 | 1,651 | +6 | +0.4% | 6,000 |
| 2022/12/26 | 1,657 | 1,657 | 1,639 | 1,645 | +2 | +0.1% | 6,600 |
| 2022/12/23 | 1,651 | 1,663 | 1,635 | 1,643 | -17 | -1% | 8,200 |
| 2022/12/22 | 1,652 | 1,660 | 1,652 | 1,660 | +8 | +0.5% | 1,700 |
| 2022/12/21 | 1,675 | 1,676 | 1,652 | 1,652 | -23 | -1.4% | 4,300 |
| 2022/12/20 | 1,659 | 1,690 | 1,659 | 1,675 | +4 | +0.2% | 5,300 |
| 2022/12/19 | 1,675 | 1,680 | 1,661 | 1,671 | -4 | -0.2% | 5,300 |
| 2022/12/16 | 1,685 | 1,685 | 1,675 | 1,675 | -15 | -0.9% | 5,800 |
| 2022/12/15 | 1,682 | 1,691 | 1,682 | 1,690 | +8 | +0.5% | 700 |
| 2022/12/14 | 1,668 | 1,682 | 1,668 | 1,682 | +14 | +0.8% | 1,800 |
| 2022/12/13 | 1,685 | 1,685 | 1,663 | 1,668 | -2 | -0.1% | 4,200 |
301～
350
件表示中 / 3457件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 156,600円 | +2.5% | - | 3.19% | 94.17倍 | 0.31倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ＶＩＳ | 108,000円 | +87.8% | +265.7% | 0.00% | 64.86倍 | 4.45倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| カイオム | 12,400円 | +2.6% | - | 0.00% | - | 6.08倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
| ノイルイミューン | 14,700円 | -5.1% | - | 0.00% | - | 1.12倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| サイフューズ | 73,200円 | +891.8% | - | 0.00% | - | 1.86倍 |
|
バイオ３Ｄプリンタを開発、自家細胞製品の製造受託も。臓器など再生医療等製品を臨床開発中 |
市場注目の銘柄
チャート関連のコラム
